186 related articles for article (PubMed ID: 17159988)
1. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
Liu TX; Becker MW; Jelinek J; Wu WS; Deng M; Mikhalkevich N; Hsu K; Bloomfield CD; Stone RM; DeAngelo DJ; Galinsky IA; Issa JP; Clarke MF; Look AT
Nat Med; 2007 Jan; 13(1):78-83. PubMed ID: 17159988
[TBL] [Abstract][Full Text] [Related]
2. Genomic Copy Number Variations in the Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients with del(5q) and/or -7/del(7q).
Zhang R; Kim YM; Wang X; Li Y; Lu X; Sternenberger AR; Li S; Lee JY
Int J Med Sci; 2015; 12(9):719-26. PubMed ID: 26392809
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of p53 provides a competitive advantage to del(5q) myelodysplastic syndrome hematopoietic stem cells during inflammation.
Muto T; Walker CS; Agarwal P; Vick E; Sampson A; Choi K; Niederkorn M; Ishikawa C; Hueneman K; Varney M; Starczynowski DT
Haematologica; 2023 Oct; 108(10):2715-2729. PubMed ID: 37102608
[TBL] [Abstract][Full Text] [Related]
4. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.
Sridhar K; Ross DT; Tibshirani R; Butte AJ; Greenberg PL
Blood; 2009 Nov; 114(23):4847-58. PubMed ID: 19801443
[TBL] [Abstract][Full Text] [Related]
5. TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q).
Tefferi A; Fleti F; Chan O; Al Ali NH; Al-Kali A; Begna KH; Foran JM; Badar T; Khera N; Shah M; Hiwase D; Padron E; Sallman DA; Pardanani A; Arber DA; Orazi A; Reichard KK; He R; Ketterling RP; Gangat N; Komrokji R
Br J Haematol; 2024 Apr; 204(4):1243-1248. PubMed ID: 38083865
[TBL] [Abstract][Full Text] [Related]
6. HSPA9/mortalin inhibition disrupts erythroid maturation through a TP53-dependent mechanism in human CD34+ hematopoietic progenitor cells.
Butler C; Dunmire M; Choi J; Szalai G; Johnson A; Lei W; Chen X; Liu L; Li W; Walter MJ; Liu T
Cell Stress Chaperones; 2024 Apr; 29(2):300-311. PubMed ID: 38508444
[TBL] [Abstract][Full Text] [Related]
7. Loss of Mll3 Catalytic Function Promotes Aberrant Myelopoiesis.
Arcipowski KM; Bulic M; Gurbuxani S; Licht JD
PLoS One; 2016; 11(9):e0162515. PubMed ID: 27610619
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients.
Helbo AS; Treppendahl M; Aslan D; Dimopoulos K; Nandrup-Bus C; Holm MS; Andersen MK; Liang G; Kristensen LS; Grønbæk K
Genes (Basel); 2015 Oct; 6(4):977-90. PubMed ID: 26473932
[TBL] [Abstract][Full Text] [Related]
9. Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML.
Barreyro L; Sampson AM; Hueneman K; Choi K; Christie S; Ramesh V; Wyder M; Wang D; Pujato M; Greis KD; Huang G; Starczynowski DT
iScience; 2024 Jun; 27(6):109809. PubMed ID: 38784013
[TBL] [Abstract][Full Text] [Related]
10. Cellular carcinogenesis in preleukemic conditions:drivers and defenses.
Ueda K; Ikeda K
Fukushima J Med Sci; 2024 Jan; 70(1):11-24. PubMed ID: 37952978
[TBL] [Abstract][Full Text] [Related]
11. Collaborative effect of Csnk1a1 haploinsufficiency and mutant p53 in Myc induction can promote leukemic transformation.
Fuchs SNR; Stalmann USA; Snoeren IAM; Bindels E; Schmitz S; Banjanin B; Hoogenboezem RM; van Herk S; Saad M; Walter W; Haferlach T; Seillier L; Saez-Rodriguez J; Dugourd AJF; Lehmann KV; Ben-Neriah Y; Gleitz HFE; Schneider RK
Blood Adv; 2024 Feb; 8(3):766-779. PubMed ID: 38147624
[TBL] [Abstract][Full Text] [Related]
12. P39/Tsugane cells are a false cell line contaminated with HL-60 cells and are not suitable for mechanistic studies in myelodysplastic syndromes.
Steensma DP
Haematologica; 2010 Jul; 95(7):1229-30. PubMed ID: 20421273
[No Abstract] [Full Text] [Related]
13. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Arber DA; Orazi A; Hasserjian R; Thiele J; Borowitz MJ; Le Beau MM; Bloomfield CD; Cazzola M; Vardiman JW
Blood; 2016 May; 127(20):2391-405. PubMed ID: 27069254
[TBL] [Abstract][Full Text] [Related]
14. CPX-351 (vyxeos) in AML.
Alfayez M; Kantarjian H; Kadia T; Ravandi-Kashani F; Daver N
Leuk Lymphoma; 2020 Feb; 61(2):288-297. PubMed ID: 31547736
[TBL] [Abstract][Full Text] [Related]
15. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.
Phillips CL; Davies SM; McMasters R; Absalon M; O'Brien M; Mo J; Broun R; Moscow JA; Smolarek T; Garzon R; Blum W; Schwind S; Marcucci G; Perentesis JP
Br J Haematol; 2013 May; 161(3):406-10. PubMed ID: 23432727
[TBL] [Abstract][Full Text] [Related]
16. 5q- myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics.
Eisenmann KM; Dykema KJ; Matheson SF; Kent NF; DeWard AD; West RA; Tibes R; Furge KA; Alberts AS
Oncogene; 2009 Oct; 28(39):3429-41. PubMed ID: 19597464
[TBL] [Abstract][Full Text] [Related]
17. DELE1 haploinsufficiency causes resistance to mitochondrial stress-induced apoptosis in monosomy 5/del(5q) AML.
Spinella JF; Chagraoui J; Moison C; Lavallée VP; Boivin I; Gracias D; Lavallée S; Carpentier GR; Beliveau F; Hébert J; Sauvageau G
Leukemia; 2024 Mar; 38(3):530-537. PubMed ID: 38102204
[TBL] [Abstract][Full Text] [Related]
18. α-catenin interaction with YAP/FoxM1/TEAD-induced CEP55 supports liver cancer cell migration.
Tang Y; Thiess L; Weiler SME; Tóth M; Rose F; Merker S; Ruppert T; Schirmacher P; Breuhahn K
Cell Commun Signal; 2023 Jun; 21(1):162. PubMed ID: 37381005
[TBL] [Abstract][Full Text] [Related]
19. The Role of CTNNA1 in Malignancies: An Updated Review.
Huang J; Wang H; Xu Y; Li C; Lv X; Han X; Chen X; Chen Y; Yu Z
J Cancer; 2023; 14(2):219-230. PubMed ID: 36741258
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
